Research Article
Clinical Profile and Treatment of Multiple Myeloma at a Tertiary Hospital in Kenya: A Five-Year Retrospective Review
Table 3
Regimens used in the treatment of multiple myeloma at KNH.
| | Regimen | Frequency (%) |
| | Chemotherapy-based | 56 (30.4%) | | Melphalan + prednisone | 36 | Other
(melphalan + cyclophosphamide + prednisone cyclophosphamide + doxorubicin + vincristine etc) | 20 | | Immunomodulator-based therapy | 113 (61.4%) | | Thalidomide-based | 107 (94.7%) | | Thalidomide + dexamethasone | 45 | | Thalidomide + melphalan + prednisone | 40 | Other
(cyclophosphamide + thalidomide + dexamethasone thalidomide + prednisone etc) | 22 | | Lenalidomide-based | 6 (5.3%) | | Bortezomib-based therapy | 15 (8.2%) | | Bortezomib + thalidomide + dexamethasone | 6 | | Bortezomib + lenalidomide + dexamethasone | 6 | | Bortezomib + dexamethasone | 2 | | Bortezomib + pomalidomide + dexamethasone | 1 |
|
|
